Member Info for MoreThanMe

Closed the last hour above resistance, looking good here.

https://imgur.com/a/1fkzwvk

It will be interesting if we start to see new institutional investors coming on board and some TR-1s in the next month. Now we have a bigger market cap, these IIs won't be held back by restrictions such as not investing in companies under 100-150m Mcaps.

SNG is looking really good today, if it can break out of the down trending wedge, we are going to shoot up very fast here today, Lansdowne must be running out of shares or close to. Graph of the breakout in link below:

https://imgur.com/a/kWAncy9

It was only a pause in the vaccine and it was one of many vaccine trials currently ongoing. If there was major negative news about vaccine trials, we will see big drops in the FTSE and SP500, so I don't think any of our rises can be attributable to the AZN vaccine trial pause.

Our rise last week was because we have broken out of a long period of consolidation, due to the company raising equity capital to increase manufacturing capacity and working capital going forward. We have cleared the overhang from the placing and have imminent news on many fronts as well as a government that is under increasing pressure to deliver testing. Entering the autumn and the flu season, many people are developing colds and coughs and releasing the importance of LFT home testing and see the value on offer here.

What is ironic is that we have gone from 55% insitutional ownership to less than 15%, so they would have to buy a lot more of the shares in the open market, making it much more difficuilt to buy cheaply.

For years, diagnostics has been the least exciting area of biotech companies and an area that big pharm companies have cut back on, or downright cut from their business. Times have changed, the big biotechs know how much growth is coming to the sector of diagnostics and how neglected it was for so many years.

AstraZeneca have today posted a listing for a new Head of Point-of-Care Diagnostics. They want in on diagnostics now. I wander which will get swallowed up first ODX or NCYT?

https://www.glassdoor.co.uk/job-listing/head-of-point-of-care-diagnostics-astrazeneca-JV_IC2662516_KO0,33_KE34,45.htm?jl=3413998286&utm_campaign=google_jobs_apply&utm_source=google_jobs_apply&utm_medium=organic

A mologic test could of course trump them all with integration into the track and trace app, so that you can test yourself prior to arrive at the airport, worplace or event. So you would take the Mologic LFT, then using the track and trace app scan the QR code on the completed Mologic LFT test, loggin the result. Your app could then be used as proof for that day or however long they deem safe.

The 3 tests at Heathrow must have been selected because they are the fastest, most accurate and furthest progressed in the development cycle, with a quick route to manufacture. So the Mologic test is further progressed and closer to market than we had originally though which is great news. When you compare the 3 tests, I think it makes sense for Heathrow to go with i-Abra when you look at a breakdown of the pros and cons of each test. But an airport is a unique situation as the $20,000 initial investment to buy one of these machines is not a barrier to entry for an airport. Below I have summarised the 3 different tests and their likely use cases.

--* A Breakdown of the 3 Heathrow tests *--
- *i-Abra: "Machine will cost less than $20,000, with cartridge testing kits about "the price of a paperback book", so expensive initial outlay and still costs around £10 for a test. Advantages are that it provides an accurate result in 30 seconds, which is hugely important in an airport environment.
- Use cases: Airports, big business, big sporting events.

- *RT-LAMP: "Experts put the cost of ‘lab in a box’ (LAMP) tests at around €40 to the consumer", provides results in 30 minutes and has great accuracy.
- Use cases: Smaller businesses, but with a high cost per test as well as initial capital outlay, the tech will need to be improved or cost reduced.

- *Mologic: Results in 10 minutes, cost will be under £10 with no initial capital outlay to buy a machine.
- Use cases: With its portability, price and ease of use will make it the most attractive test in many different situations: businesses of all sizes, small-mid size events, home use, travel, family celebrations like christmas.

Sources:
i-Abra: https://www.fiercebiotech.com/medtech/20-second-coronavirus-screening-test-piloted-at-u-k-s-heathrow-airport
RT-LAMP: https://www.telegraph.co.uk/travel/news/test4travel-quarantine-testing-airport/

@Obelix The finCap target is under review and has been for a while, but they have done a sum of the parts valuation, which I have took screenshots of and added to the link below. You can find the complete broker company note on finCaps website, but you do have to sign up to gain access.

https://imgur.com/a/r5K462n

Strong day here, nice to see it close above 72.6p. Can't wait to hear more from the company about orders capacity and plans going forward into 2021. I hope we can look forward to another investor meets company, that was a gold mine of information.

Excellent day today on a technical basis. Broke the 72.6p resistance and retested it twice, it will be interesting to see how we close today. Looking strong, graphs attached in link below.

https://imgur.com/a/FUDFTg3

There have been some big buys showing up here, so there must be some very confident people around, a good sign.

For those that can't be bothered to follow a link here is a breakdown of the use of placing and open offer proceeds:

- £1.1m | COVID-19 –ELISA Testing: 275k tests per week to 1m tests per week
- £3.0m | COVID-19 –LFT: 100k tests per week to 500k tests per week (£1.1m) extended to 1.0m tests per week (£1.9m)
- £0.4m | VISITECT® CD4Margin Improvement
- £2.7m | Expand Lateral Flow Product Portfolio
- £1.0m | Repayment of Overdraft Facility
- £2.3m | Working Capital estimate
-----------
- £10.5m | Total

This was back in July, so maybe the use of the proceeds may have changed slightly, but that was the last we heard from the company as to how they were using the funds.

@Nskno1 Only £1.0m was used to repay the overdraft facility, please see screenshot slide below to see the use of placing and open offer proceeds:

https://imgur.com/a/nHmLEdz

@antelope The labs can't keep up with testing symptomatic people yet, let alone asymptomatic people. As a result the gov desperately don't want lots of asymptomatic people coming forward to get tested as it would completely overwhelm them.

So the government has aspiration to test asymptomatic people in the future with the aid of LFT, but we arent there yet and the gov is making that clear, so there isn't an overnight influx of asymptomatic people coming forward fro testing.

One of the reasons ODX is so undervalued IMO is because of its high ownership by II prior to the UK-RTC formation at cerca 52.7%. Whenever we have had big news these II have sold into the rises and the increase in share price has been muted as a result, I am not complaining as if it wasn't for them I wouldn't have had such an attractive buy in price. But as a result, we haven't seen as larger increases in SP compared to some of our fellow Covid stocks.

If we assume L&G are at 2% now, we have gone from 52.7% to 14.75% II reported holdings, with David Evans accounting for 3.76% and Sneller with 8.99%. David Evans is the ex-chairman, so I don't think he will sell his stake, which only leaves Sneller. We are running out of II's to sell into the rises and when we do, we will rise up unrestricted and finnaly an mcap that better represents the value on offer in Omega.

I holdings are much easier to visualise graphically, so I have added a link below showing graphs I have made displaying the II holding percentages over the last 3 years.

https://imgur.com/a/csu7sRD

Fantastic news, onwards and upwards

Nice little shake after the rise, to retest the 72.6p resistance before moving up higher. It is amazing how quickly sentiment can change in a stock, I just don't understand why people weren't seeing the potential we had on offer when we were in the 50p, we were there long enough after all!

There is strong buying at 180p and now this has turned, its only a matter of time till we are back above £2, when Lansdowne is out, we will rocket here.

Well done to those that brought into the weakness this morning, I think at 180p there will be a lot of buyers as there is so much value on offer here, so I doubt we will drop below 180p again.